Introduction {#s1}
============

The rapid introduction of massive parallel sequencing (MPS) into clinical genetics services is enabling the screening of multiple breast cancer susceptibility genes in one assay at reduced cost for women who are at increased risk of breast (and other) cancer. These gene panels now typically include the so-called 'moderate-risk' breast cancer susceptibility genes, including *PALB2*, *CHEK2* and *ATM.*[@R1] However, mutations in these genes are individually extremely rare and limited data are available with which to accurately estimate the risk of cancer associated with them.

Estimation of the age-specific cumulative risk (penetrance) of breast cancer associated with specific mutations in these three genes has been limited to those that have been observed more frequently, such as *PALB2* c.1592delT (a Finnish founder mutation), *PALB2* c.3113G\>A and *ATM* c.7271T\>G. These mutations have been estimated to be associated with a 40% (95% CI 17% to 77%), 91% (95% CI 44% to 100%) and 52% (95% CI 28% to 80%) cumulative risk of breast cancer to the age of 70 years, respectively.[@R4] These findings, based on segregation analyses in families of population-based case series, indicate that at least some mutations in these 'moderate-risk' genes are associated with a breast cancer risk comparable to that of the average pathogenic mutation in *BRCA2*: 45% (95% CI 31% to 56%).[@R8] However, such estimates are imprecise and, moreover, may be confounded by modifying genetic variants or other familial risk factors.

Case-control studies provide an alternative approach to estimating cancer risks associated with specific variants. This design can estimate the relative risk directly, without making assumptions about the modifying effects of other risk factors. However, because these variants are rare, such studies need to be extremely large to provide precise estimates.

The clearest evidence for association, and the most precise breast cancer risk estimates, for rare variants in *PALB2, CHEK2* and *ATM* relate to protein truncating and splice-junction variants.[@R9] [@R10] However, studies based on mutation screening in case-control studies, combined with stratification of variants by their evolutionary likelihood suggest that at least some evolutionarily unlikely missense substitutions are associated with a similar risk to those conferred by truncating mutations.[@R11] For example, Tavtigian *et al*[@R12] estimated an OR of 2.85 (95% CI 0.83 to 4.86) for evolutionarily unlikely missense substitutions in the 3′ third of *ATM*, which is comparable to that for truncating variants. Specifically, *ATM* c.7271C\>G has been associated with a more substantial breast cancer risk in several studies.[@R7] [@R13] Le Calvez-Kelm *et al*,[@R11] estimated that the ORs associated with rare mutations in *CHEK2* from similarly designed studies were 6.18 (95% CI 1.76 to 21.8) for rare protein-truncating and splice-junction variants and 8.75 (95% CI 1.06 to 72.2) for evolutionarily unlikely missense substitutions.[@R11]

It is plausible that monoallelic mutations in *PALB2*, *CHEK2* and *ATM* could be associated with increased risk of cancers other than breast cancer, as has been observed for *BRCA1* and *BRCA2* and both ovarian and prostate cancers.[@R14] However, with the exception of pancreatic cancer in *PALB2* carriers, there is little evidence to support or refute the existence of such associations, although a few individually striking pedigrees have been observed.[@R4] [@R8] [@R18]

In this study we selected rare genetic variants on the basis that they had been observed in breast cancer candidate gene case-control screening projects involving *PALB2*, *CHEK2* or *ATM*. These included three rare variants in *PALB2*: the protein truncating variants c.1592delT (p.Leu531Cysfs)[@R4] and c.3113 G\>A (p.Trp1038\*)[@R6] and the missense variant c.2816T\>G, (p.Leu939Trp), six rare missense variants in CHEK2: c.349A\>G (p.Arg117Gly) and c.1036C\>T (p.Arg346Cys) predicted to be deleterious on the basis of evolutionary conservation,[@R11] c.538C\>T (p.Arg180Cys), c.715G\>A (p.Glu239Lys), c.1312G\>T (p.Asp438Tyr) and c.1343T\>G (p.Ile448Ser) and *ATM* c.7271T\>G (p.Val2424Gly).[@R7] We assessed the association of these variants with breast, ovarian and prostate risk by case-control analyses in three large consortia participating in the Collaborative Oncological Gene-environment Study.[@R21] [@R22]

Methods {#s2}
=======

Participants {#s2a}
------------

Participants were drawn from studies participating in three consortia as follows:

The *Breast Cancer Association Consortium (BCAC),* involving a total of 48 studies: 37 of women from populations with predominantly European ancestry (42 671 cases and 42 164 controls), 9 of Asian women (5795 cases and 6624 controls) and 2 of African-American women (1046 cases and 932 controls). All cases had invasive breast cancer. The majority of studies were population-based or hospital-based case-control studies, but some studies of European women oversampled cases with a family history or with bilateral disease (see online [supplementary table](#SM1){ref-type="supplementary-material"} S1). Overall, 79% of BCAC cases with known Estrogen Recptor (ER) status (23% missing) are ER-positive. The proportion of cases selected by family history that are ER-positive is 78% (38% missing).
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The *Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)* involving a total of 26 studies: 25 included men with European ancestry (22 301 cases and 22 320 controls) and 3 included African-American men (623 cases and 569 controls). The majority of studies were population-based or hospital-based case-control studies (see online [supplementary table](#SM1){ref-type="supplementary-material"} S2).

The *Ovarian Cancer Association Consortium (OCAC)*, involving a total of 46 studies. Some studies were case-only and their data were combined with case-control studies from the same geographical region (leaving 36 study groupings). Of these groupings, 33 included women from populations with predominantly European ancestry (16 287 cases (14 542 with invasive disease) and 23 491 controls), 25 included Asian women (813 cases (720 with invasive disease) and 1574 controls), 17 included African-American women (186 cases (150 with invasive disease) and 200 controls) and 29 included women of other ethnic origin (893 cases (709 with invasive disease) and 864 controls). The majority of studies were population-based or hospital-based case-control studies (see online [supplementary table](#SM1){ref-type="supplementary-material"} S3).

Details regarding sample quality control have been published previously.[@R22] [@R23] All study participants gave informed consent and all studies were approved by the corresponding local ethics committees (see online [supplementary table](#SM1){ref-type="supplementary-material"}s S1--S3).

Variant selection {#s2b}
-----------------

We selected for genotyping 13 rare mutations that had been observed in population-based case-control mutation screening studies. These variants were *PALB2* (c.1592delT, p.Leu531Cysfs;[@R4] [@R5] [@R10] c.2323C\>T p.Gln775\*;[@R20] c.2816T\>G, p.Leu939Trp;[@R2] [@R20] c.3113G\>A, p.Trp1038\*;[@R2] [@R6] [@R20] c.3116delA, p.Asn1039IIefs;[@R2] [@R6] [@R20] c.3549C\>G, p.Tyr1183\*[@R2]), *CHEK2* (c.349A\>G, p.ArgR117Gly; c.538C\>T, p.Arg180Cys; c.715G\>A p.Glu239Lys; c.1036C\>T, p.Arg346Cys; c.1312G\>T, p.Asp438Tyr; c.1343T\>G, p.Ile448Ser)[@R11] and *ATM* (c.7271T\>G, p.Val2424Gly)[@R7] [@R13] [@R24] see [table 1](#JMEDGENET2016103839TB1){ref-type="table"}. A DNA sample carrying each of these variants was included in a plate of control DNAs that was distributed to each genotyping centre to assist with quality control and genotype calling.

###### 

Rare genetic variants included in the iCOGS array.

  Gene      Variant\*    Amino acid\*     dbSNP rs      Breast cancer risk estimates   Align-GVGD      Reference(s)   Designed‡                             Genotyped   
  --------- ------------ ---------------- ------------- ------------------------------ --------------- -------------- ------------------------------------- ----------- -----
  *PALB2*   c.1592delT   p.Leu531Cysfs    rs180177102   3.94 (1.5-12.1)§               40% (17--77)    na             [@R4]^,^ [@R5]^,^ [@R10]              Yes         Yes
            c.2323C\>T   p.Gln775\*       rs180177111                                                  na             [@R25]^,^ [@R26]                      No          No
            c.2816T\>G   p.Leu939Trp      rs45478192                                                   C55            [@R20]                                Yes         Yes
            c.3113G\>A   p.Trp1038\*      rs180177132                                  95% (44--100)   na             [@R2]^,^ [@R6]^,^ [@R20]              Yes         Yes
            c.3116delA   p.Asn1039Ilefs   rs180177133                                                  na             [@R2]                                 No          No
            c.3549C\>G   p.Tyr1183\*      rs118203998                                                  na             [@R2]                                 No          No
  CHEK2     c.349A\>G    p.Arg117Gly      rs28909982    8.75 (1.06--72.2)¶                             C65            [@R11]                                Yes         Yes
            c.538C\>T    p.Arg180Cys      rs77130927    2.47 (0.45--13.49)\*\*                         C25            [@R11]                                Yes         Yes
            c.715G\>A    p.Glu239Lys      rs121908702   1.82 (0.62--5.34)††                            C15            [@R11]                                Yes         Yes
            c.1036C\>T   p.Arg346Cys      na            8.75 (1.06--72.2)¶                             C65            [@R11]                                Yes         Yes
            c.1312G\>T   p.Asp438Tyr      na            2.47 (0.45--13.49)\*\*                         C25            [@R11]                                Yes         Yes
            c.1343T\>G   p.Ile448Ser      rs17886163    1.82 (0.62--5.34)††                            C15            [@R11]                                Yes         Yes
  ATM       c.7271T\>G   p.Val2424Gly     rs28904921                                   52% (28--80)    C65            [@R7]^,^ [@R13]^,^ [@R23]^,^ [@R27]   Yes         Yes

\*Human Genome Variation Society (HGVS); reference sequences PALB2, NM_024675.3, NP_078951.2; CHEK2, NM_007194.3, NP_009125.1; ATM, NM_000051.3, NP_000042.3.

†Age-specific cumulative risk of breast cancer to age 70 years.[@R5][@R7]

‡Able to be designed for measurement on the custom Illumina iSelect genotyping array.[@R21] [@R22]

**§**Breast cancer cases unselected for family history of breast cancer.[@R4]

¶OR estimated in a combined group of C65 CHEK2 variants.[@R11]

\*\*OR estimated in a combined group of C25 CHEK2 variants.[@R11]

††OR estimated in a combined group of C15 CHEK2 variants.[@R11]

na, not available.

Genotyping {#s2c}
----------

Three *PALB2* variants c.2323C\>T (p.Gln775\*), c.3116delA (p.Asn1039IIefs) and c.3549C\>G (p.Tyr1183\*) were unable to be designed for measurement on the custom Illumina iSelect genotyping array and were not considered further ([table 1](#JMEDGENET2016103839TB1){ref-type="table"}). Genotyping was conducted using a custom Illumina Infinium array (iCOGS) in four centres, as part of a multiconsortia collaboration as described previously.[@R22] Genotypes were called using Illumina\'s proprietary GenCall algorithm and then, for the data generated from the rare variant probes, manually confirmed with reference to the positive control sample. Two per cent of samples were provided in duplicate by all studies and 270 HapMap2 samples were genotyped in all four genotyping centres. Subjects with an overall call rate \<95% were excluded. Plates with call rates \<90% were excluded on a variant-by-variant basis. Cluster plots generated for all of the 10 rare variants were manually checked to confirm automated calls (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1).

Statistical methods {#s2d}
-------------------

The association of each variant with breast, prostate and ovarian cancer risk was assessed using unconditional logistic regression to estimate ORs for carriers versus non-carriers, adjusting for study (categorical). p Values were determined by the likelihood ratio test comparing models with and without carrier status as a covariate. We also applied conditional logistic regression, defining risk sets by study, and found that this made no difference to the OR estimates, CIs or p values to two significant figures; since model convergence was a problem for this latter regression analysis, all subsequent analyses were based on unconditional logistic regression. For the main analyses of breast cancer risk in European women, we also included as covariates the first six principal components, together with a seventh component specific to one study (Leuven Multidisciplinary Breast Centre (LMBC)) for which there was substantial inflation not accounted for by the components derived from the analysis of all studies. Addition of further principal components did not reduce inflation further. Data from all breast cancer studies were included to assess statistical significance. Data from cases selected for inclusion based on personal or family history of breast cancer were excluded in order to obtain unbiased OR estimates for the general population of white European women (leaving 37 039 cases and 38 260 controls from 32 studies). Multiple testing was adjusted for using the Benjamini-Hochberg procedure to control the false discovery rate, with a significance threshold of 0.05.[@R25] Reported p values are unadjusted unless otherwise stated. Reported CIs are all nominal. We included two race-specific principal components in each of the main breast cancer analyses of Asian and African-American women. Similar analyses were conducted using the data from PRACTICAL and OCAC, consistent with those used previously.[@R23] [@R26] All analyses were carried out using Stata: Release V.10 (StataCorp, 2008).

Results {#s3}
=======

PALB2 {#s3a}
-----

In BCAC, *PALB2* c.1592delT (Leu531Cysfs) was only observed in 35 cases and 6 controls, all from four studies from Sweden and Finland (Helsinki Breast Cancer Study (HEBCS), Kuopio Breast Cancer Project (KBCP), Oulu Breast Cancer Study (OBCS) and Karolinska Mammography Project for Risk Prediction Breast Cancer (pKARMA); see online [supplementary table](#SM1){ref-type="supplementary-material"} S1), giving strong evidence of association with breast cancer risk (p=7.1×10^−5^); the OR estimate was 4.52 (95% CI 1.90 to 10.8) based on all studies and 3.44 (95% CI 1.39 to 8.52) based on unselected cases and controls ([table 2](#JMEDGENET2016103839TB2){ref-type="table"}). We also found evidence of heterogeneity by ER status (p=0.0023), the association being stronger for ER-negative disease (OR 6.49 (95% CI 2.17 to 19.4) versus 2.24 (95% CI 1.05 to 7.24) for ER-positive disease).

###### 

Summary results from Breast Cancer Association Consortium studies of white Europeans **(**42 671 invasive breast cancer cases and 42 164 controls)

  -------------------------------------------------------------------------------------------------------------------------------------
  Variant                           Frequency\*\   Frequency\*\   OR (95% CI)           LRT\         OR† (95% CI)          LRT\
                                    Controls       Cases                                p Value                            p Value†
  --------------------------------- -------------- -------------- --------------------- ------------ --------------------- ------------
  *PALB2*§                                                                                                                 

   **c.1592delT (p.Leu531Cysfs)**   0.00014        0.00082        4.52 (1.90 to 10.8)   7.1×10^−5^   3.44 (1.39 to 8.52)   0.003

   c.2816T\>G (p.Leu939Trp)         0.00342        0.00352        1.05 (0.83 to 1.32)   0.70         1.03 (0.80 to 1.32)   0.82

   **c.3113G\>A (p.Trp1038\*)**     0.00019        0.00101        5.93 (2.77 to 12.7)   6.9×10^−8^   4.21 (1.84 to 9.60)   1.2×10^−4^

  ***CHEK2***                                                                                                              

   **c.349A\>G (p.Arg117Gly)**      0.00043        0.00103        2.26 (1.29 to 3.95)   0.003        2.03 (1.10 to 3.73)   0.020

   **c.538C\>T (p.Arg180Cys)**      0.00337        0.00370        1.33 (1.05 to 1.67)   0.016        1.34 (1.06 to 1.70)   0.015

   c.715G\>A (p.Glu239Lys)          0.00021        0.00035        1.70 (0.73 to 3.93)   0.210        1.47 (0.60 to 3.64)   0.40

   c.1036C\>T (p.Arg346Cys)         0.00005        0.00021        5.06 (1.09 to 23.5)   0.017        3.39 (0.68 to 16.9)   0.11

   c.1312G\>T (p.Asp438Tyr)         0.00078        0.00082        1.03 (0.62 to 1.71)   0.910        0.87 (0.49 to 1.52)   0.62

   c.1343T\>G (p.Ile448Ser)‡        0.00002        0              --                    --           --                    --

  ***ATM***                                                                                                                

   **c.7271T\>G (p.Val2424Gly)**    0.00002        0.00028        11.6 (1.50 to 89.9)   0.0012       11.0 (1.42 to 85.7)   0.0019
  -------------------------------------------------------------------------------------------------------------------------------------

\*Proportion of subjects carrying the variant.

†Excluding women from five studies that selected all cases based on family history or bilateral disease and the subset of selected cases from other studies (based on 34 488 unselected cases and 34 059 controls).

‡*CHEK2* c.1343T\>G (p.Ile448Ser) was only observed in one control and no cases of white European origin.

§*PALB2* c.3113G\>A (p.Trp1038\*) only observed in the UK, Australia, the USA and Canada. *PALB2* c.1592delT (p.Leu531Cysfs) only observed in Finland and Sweden.

LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.

*PALB2* c.3113G\>A (p.Trp1038\*) was identified in 44 cases and 8 controls from nine BCAC studies. Only one carrier of the variant was of non-European origin. Strong evidence of association with breast cancer risk was observed (p=6.9×10^−8^), with an estimated OR of 5.93 (95% CI 2.77 to 12.7) based on all studies and 4.21 (95% CI 1.85 to 9.61) based on unselected cases and controls. There was no evidence of a differential association by ER status (p=0.15).

Based on unselected cases, the estimated OR associated with carrying either of these *PALB2* variants (c.1592delT or c.3113G\>A) was 3.85 (95% CI 2.09 to 7.09).

*PALB2* c.2816T\>G (p.Leu939Trp) was identified in 150 cases and 145 controls and there was no evidence of association with risk of breast cancer. There was no evidence of association with risk of prostate or ovarian cancer for any of the three *PALB2* variants (see [tables 3](#JMEDGENET2016103839TB3){ref-type="table"} and [4](#JMEDGENET2016103839TB4){ref-type="table"}).

###### 

Summary results from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome studies for white European men\* (22 301 prostate cancer cases and 22 320 controls)

  -----------------------------------------------------------------------------------------
  Variant                       Frequency†\   Frequency†\   OR (95% CI)           LRT\
                                Controls      Cases                               p Value
  ----------------------------- ------------- ------------- --------------------- ---------
  *PALB2*                                                                         

   c.1592delT (p.Leu531Cysfs)   0.00018       0.00031       2.06 (0.59 to 7.11)   0.24

   c.2816T\>G (p.Leu939Trp)     0.00354       0.00381       0.95 (0.69 to 1.29)   0.73

   c.3113G\>A (p.Trp1038\*)     0.00045       0.00027       0.49 (0.18 to 1.36)   0.16

  *CHEK2*‡                                                                        

   c.349A\>G (p.Arg117Gly)      0.00063       0.00081       1.46 (0.71 to 3.02)   0.30

   c.538C\>T (p.Arg180Cys)      0.00341       0.00296       1.02 (0.73 to 1.44)   0.90

   c.715G\>A (p.Glu239Lys)      0.00018       0.00027       1.47 (0.41 to 5.35)   0.55

   c.1036C\>T (p.Arg346Cys)     0.00018       0.00022       1.07 (0.28 to 4.07)   0.93

   c.1312G\>T (p.Asp438Tyr)     0.00049       0.00103       2.21 (1.06 to 4.63)   0.03

   c.1343T\>G (p.Ile448Ser)     0             0.00009       --                    --

   c.1343T\>G (Africans§)       0.019         0.057         3.03 (1.53 to 6.03)   0.001

  ATM                                                                             

   c.7271T\>G (p.Val2424Gly)    0.00004       0.00027       4.37 (0.52 to 36.4)   0.17
  -----------------------------------------------------------------------------------------

\*For white European men, unless otherwise indicated.

†Proportion of subjects carrying the variant.

‡*CHEK2* c.1343T\>G (p.Ile448Ser) was the only *CHEK2* variant observed in African men and was identified in two cases and no controls of white European origin.

§Based on data from 623 and 569 African-American cases and controls, respectively.

LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.

###### 

Summary results from the Ovarian Cancer Association Consortium studies for white European women (14 542 invasive ovarian cancer cases and 23 491 controls)

  -------------------------------------------------------------------------------------------
  Variant                       Frequency\*\   Frequency\*\   OR (95% CI)           LRT\
                                Controls       Cases                                p Value
  ----------------------------- -------------- -------------- --------------------- ---------
  *PALB2*                                                                           

   c.1592delT (p.Leu531Cysfs)   0.00004        0.00012        2.50 (0.21 to 29.1)   0.45

   c.2816T\>G (p.Leu939Trp)     0.00413        0.00399        0.96 (0.69 to 1.34)   0.81

   c.3113G\>A (p.Trp1038\*)     0.00034        0.00031        1.34 (0.36 to 4.97)   0.66

  *CHEK2*                                                                           

   c.349A\>G (p.Arg117Gly)      0.00038        0.00031        1.07 (0.32 to 3.60)   0.92

   c.538C\>T (p.Arg180Cys)      0.00128        0.00160        1.49 (0.83 to 2.67)   0.18

   c.715G\>A (p.Glu239Lys)      0.00021        0.00037        1.47 (0.42 to 5.22)   0.54

   c.1036C\>T (p.Arg346Cys)‡    0              0              --                    --

   c.1312G\>T (p.Asp438Tyr)     0.00081        0.00074        0.92 (0.42 to 1.99)   0.83

   c.1343T\>G (p.Ile448Ser)     0.00009        0              --                    --

  *ATM*                                                                             

   c.7271T\>G (p.Val2424Gly)    0              0.00012        --                    --
  -------------------------------------------------------------------------------------------

\*Proportion of subjects carrying the variant.

‡c.1036C\>T (p.Arg346Cys) was not observed in any sample.

LRT, likelihood ratio test; OR, OR for carriers of the variant versus common-allele homozygotes, adjusted for study and seven principal components.

CHEK2 {#s3b}
-----

*CHEK2* c.349A\>G (p.Arg117Gly) was identified in 44 cases and 18 controls in studies participating in BCAC; all of these women were of European origin. We found evidence of association with breast cancer (p=0.003), with little change in the OR after excluding selected cases (OR 2.03 (95% CI 1.10 to 3.73)).

*CHEK2* c.538C\>T (p.Arg180Cys) was identified in 158 breast cancer cases and 142 controls in studies of white Europeans. Evidence of association with breast cancer risk (p=0.016) was observed, with an unbiased OR estimate of 1.34 (95% CI 1.06 to 1.70). A consistent OR estimate was observed for Asian women, based on 45 case and 45 control carriers (OR 1.16 (95% CI 0.75 to 1.76)).

*CHEK2* c.715G\>A (p.Glu239Lys) mutations were identified in 15 cases and 9 controls, all European women participating in BCAC and no evidence of association with risk of breast cancer was observed (p=0.21).

*CHEK2* c.1036C\>T (p.Arg346Cys) was identified in nine cases from seven studies and two controls from two different studies in BCAC (neither control carrier was from a study that had case carriers), all of European origin. We found evidence of association with breast cancer risk (p=0.017) with reduced OR estimate of 3.39 (95% CI 0.68 to 16.9) after excluding selected cases.

None of the above four *CHEK2* variants (*CHEK2* c.349A\>G (p.Arg117Gly); c.538C\>T (p.Arg180Cys); c.715G\>A (p.Glu239Lys) and c.1036C\>T (p.Arg346Cys)) were found to be associated with an increased risk of prostate or ovarian cancer ([tables 3](#JMEDGENET2016103839TB3){ref-type="table"} and [4](#JMEDGENET2016103839TB4){ref-type="table"}). *CHEK2* variant c.1312G\>T (p.Asp438Tyr) was not associated with risk of breast cancer for European women (p=0.91). Variant c.1343T\>G (p.Ile448Ser) was not observed in any breast cancer cases of European or Asian origin. It was detected in 48 cases and 29 controls of African origin, giving weak evidence of association (OR 1.52 (95% CI 0.95 to 2.43, p=0.083)). *CHEK2* c.1312G\>T (p.Asp438Tyr) was identified in 23 cases and 11 controls from PRACTICAL, all European, providing evidence of association with prostate cancer risk (OR 2.21 (95% CI 1.06 to 4.63, p=0.030)). *CHEK2* c.1343T\>G (p.Ile448Ser) was observed in 35 cases and 11 controls, all African, participating in PRACTICAL and was also associated with an increased risk of prostate cancer (OR 3.03 (95% CI 1.53 to 6.03, p=0.00059)). There was no evidence that these *CHEK2* variants were associated with risk of ovarian cancer ([table 4](#JMEDGENET2016103839TB4){ref-type="table"}).

ATM {#s3c}
---

ATM c.7271T\>G (p.Val2424Gly) was identified in 12 cases and 1 control in studies participating in BCAC, all of European origin, giving evidence of association with breast cancer risk (p=0.0012). The OR estimate based on unselected studies was 11.0 (95% CI 1.42 to 85.7). There was no evidence of association of this variant with prostate or ovarian cancer risk (see [tables 3](#JMEDGENET2016103839TB3){ref-type="table"} and [4](#JMEDGENET2016103839TB4){ref-type="table"}).

Discussion {#s4}
==========

The present report adds to an accumulating body of evidence that at least some *rare variants* in so-called 'moderate-risk' genes are associated with an increased risk of breast cancer that is of clinical relevance.

These findings are presented at a time when detailed information about variants in these genes is becoming more readily available via the translation of diagnostic genetic testing from Sanger sequencing-based testing platforms to MPS platforms that test panels of genes in single assays.[@R27] The vast majority of information about *PALB2*, *CHEK2* and *ATM*, variants generated from these new testing platforms is not being used in clinical genetics services due to lack of reliable estimates of the cancer risk associated with individual variants, or groups of variants, in each gene. Previous analyses have been largely based on selected families, relying on data on the segregation of the variant. The present study is by far the largest to take a case-control approach. Consistent with previous reports,[@R5] [@R9] [@R11] *PALB2* c.3113G\>A (p.Trp1038\*), *PALB2* c.1592delT (p.Leu531Cysfs) and *ATM* c.7271T\>G (p.Val2424Gly) were found to be associated with substantially increased risk of breast cancer all with associated relative risk estimates of 3.44 or greater.

The estimates for the two loss-of-function *PALB2* variants (c.1592delT and c.3113G\<A) were consistent with each other and with estimates based on segregation analysis.[@R5] [@R6] [@R9] We found no evidence of association with breast cancer for *PALB2* c.2816T\>G (p.Leu939Trp), with an upper 95% confidence limit excluding an OR \>1.5 which is notable given the Align-Grantham Variation Granthan Deviation (Align-GVGD) score and the observed impact on protein function.[@R30]

The estimate for *ATM* c.7271T\>G (p.Val2424Gly) was also consistent with that found by segregation analysis.[@R7] [@R13] The substantial increased risk of breast cancer associated with *ATM* c.7271T\>G (p.Val2424Gly) could be due to the reduction in kinase activity (with near-normal protein levels) observed for ATM p.Val2424Gly,[@R31] thus this variant is likely to be acting as a dominant negative mutation.[@R32]

In contrast, we found no evidence of an association with risk of prostate or ovarian cancer with any of these three variants: however, the confidence limits were wide; based on the upper 95% confidence limit we could exclude an OR of \>1.4 for prostate cancer for the loss-of-function *PALB2* c.3113G\>A and 1.9 for c.1592delT and c.3113G\>A combined.

We analysed six rare missense variants in *CHEK2*. Two of these (*CHEK2* c.349A\>G (p.Arg117Gly; rs28909982) and c.1036C\>T (p.Arg346Cys)) had evidence of a significant impact on the protein based on in silico prediction. We proposed these variants for inclusion in the iCOGS design as they had been identified in 3/1242 cases and 1/1089 controls and 3/1242 cases and 0/1089 controls, respectively, in a population-based case-control mutation screening study of CHEK2.[@R11] In that study, Le Calvez-Kelm *et al*, estimated an OR of 8.75 (95% CI 1.06 to 72.2) for variants with an Align-GVGD score C65 (based on nine cases and one control). The current analysis provides confirmatory evidence of this association in a much larger sample (OR 2.18 (95% CI 1.23 to 3.85)) including 40 unselected case and 18 control carriers. The evidence that *CHEK2* is a breast cancer susceptibility gene is largely based on studies of protein truncating variants, in particular *CHEK2* 1100delC.[@R33] Reports of the association of the missense variant I157T, (C15) and breast cancer risk have been conflicting but a large meta-analysis involving 15 985 breast cancer cases and 18 609 controls estimated a modest OR of 1.58 (95% CI 1.42 to 1.75).[@R34] We also found evidence (p=0.015) of an association for c.538C\>T (Align-GVGD C25); OR 1.34 (95% CI 1.06 to 1.70), a risk comparable to I157T.

The p values reported above have not been adjusted for multiple testing. This was not considered appropriate for the associations with breast cancer risk of *PALB2* c.1592delT, c.3113G\>A and *ATM* c.7271T\>G because these associations had previously been reported; our aim was to more precisely estimate the associated relative risks. All three associations with breast cancer risk reported for *CHEK2* variants remained statistically significant after adjusting for the other tests conducted in relation to breast cancer risk, but not after correcting for all tests for all cancers. Nevertheless, the findings for *CHEK2* c.349A\>G and c.1036C\>T confirmed those reported previously, although collectively. The association observed with *CHEK2* c.538C\>T requires independent replication.

Do this approach and new data have an impact on clinical recommendations for women and families carrying these rare genetic variants? Although age-specific cumulate risks for cancer are more informative for genetic counselling and clinical management of carriers, our study provides information that is relevant to clinical recommendations. As discussed in Easton *et al*,[@R35] a relative risk of 4 will place a woman in a 'high-risk' category (in the absence of any other risk factor) and a relative risk between 2 and 4 will place a woman in this category if other risk factors are present. Thus, several of the variants included in this report (*PALB2* c.1592delT; c.3113G\>A *ATM* c.7271T\>G) would place the carrier in a high-risk group, especially if other risk factors, such as a family history, are present. The high level of breast cancer risk associated with *PALB2* c.1592delT and c.3113G\>A reported here is consistent with the penetrance estimate reported for a group of loss-of-function mutations in *PALB2*[@R9] and has an advantage in terms of clinical utility that the estimates in this study have been made at a mutation-specific level. Therefore, this work provides important information for risk reduction recommendations (such as prophylactic mastectomy and potentially salpingo-oophorectomy) for carriers of these variants. However, further prospective research is required to characterise these risks and to understand the potential of other risk-reducing strategies such as salpingo-oophorectomy and chemoprevention.

The consistency of the relative risk estimates with those derived through family based studies supports the hypothesis that these variants combine multiplicatively with other genetic loci and familial risk factors; this information is critical for deriving comprehensive risk models. Even with very large sample sizes such as those studied here, however, it is still only possible to derive individual risk estimates for a limited set of variants, and even for these variants the estimates are still imprecise. This internationally collaborative approach also has limited capacity to improve risk estimates for rare variants that are only observed in specific populations. Inevitably, therefore, risk models will depend on combining data across multiple variants, using improved in silico predictions and potentially biochemical/functional evidence to synthesise these estimates efficiently. It will also be necessary develop counselling and patient management strategies that can accommodate a multifactorial approach to variant classification.
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